Leerink cut #$BMY and raised #$ZNTL. Barclays lowered #$QURE. Cantor upgraded #$RZLT. New Buy calls on #$OVID, #$MRVI, and #$RGNX. notreload.xyz/xy/mixed-bio...
Mixed Biotech Calls: BMY, QURE Cuts; RZLT, ZNTL Upgrades
Leerink cut Bristol Myers and raised Zentalis. Barclays lowered uniQure. Cantor upgraded Rezolute. New Buy calls on Ovid, Maravai, and Regenxbio.
notreload.xyz
October 5, 2026 at 9:32 PM
#$RGNX Mizuho initiates with Outperform, PT $22 vs current ~$7.60 — roughly 189% implied upside.
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
October 5, 2026 at 9:38 AM
#$RGNX Mizuho initiates with Outperform, PT $22 vs current ~$7.60 — roughly 189% implied upside.
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
September 25, 2026 at 8:21 AM
Small-cap stocks with declining money flow, Thur Sept 24th - #$TIGR #$STOK #$RGNX #$QURE #$PDYN #$NAMM #$LFMD #$INO #$HCWB #$GOGO #$FLD #$CAPR #$BEEM #$ALXO #$KMPR #$HMN #$EQBK #$CCO #$BHK #$ACRE - More: crystalequityresearch.com/trade-alerts... - #smallcap
Trade Alerts, Thursday September 24, 2026 – Crystal Equity Research
crystalequityresearch.com
September 24, 2026 at 10:01 PM
🚨 $RGNX
On September 23, 2026, REGENXBIO Inc. and The Trustees of the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC and Catalent, Inc. to resolve all patent infringement litigation alleging infringement of U.S. P...
On September 23, 2026, REGENXBIO Inc. and The Trustees of the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC and Catalent, Inc. to resolve all patent infringement litigation alleging infringement of U.S. P...
SEC Filing: RGNX
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 8:08 PM
🚨 $RGNX
On September 23, 2026, REGENXBIO Inc. and The Trustees of the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC and Catalent, Inc. to resolve all patent infringement litigation alleging infringement of U.S. P...
On September 23, 2026, REGENXBIO Inc. and The Trustees of the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC and Catalent, Inc. to resolve all patent infringement litigation alleging infringement of U.S. P...
Another FDA setback for RGNX, and with the resubmission timeline already slipping, the focus now has to be on what the data and safety profile can actually support.
September 22, 2026 at 6:53 PM
Another FDA setback for RGNX, and with the resubmission timeline already slipping, the focus now has to be on what the data and safety profile can actually support.
Board additions are notable, but with RGNX still facing FDA uncertainty, execution and a clear path to resubmission matter more than another headline.
September 22, 2026 at 6:40 PM
Board additions are notable, but with RGNX still facing FDA uncertainty, execution and a clear path to resubmission matter more than another headline.
REGENXBIO (#$RGNX) Stock Hub
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/regenxbio-st...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/regenxbio-st...
September 19, 2026 at 7:20 PM
REGENXBIO (#$RGNX) Stock Hub
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/regenxbio-st...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/regenxbio-st...
Regenx said it was moving toward refiling, then the FDA hold hit and now there’s no near-term resubmission
That's not "timing problem". It raises real questions about whether the data package is strong enough #$RGNX
www.fiercebiotech.com/biotech/fda-...
That's not "timing problem". It raises real questions about whether the data package is strong enough #$RGNX
www.fiercebiotech.com/biotech/fda-...
Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings
The FDA has put a clinical hold on Regenxbio’s RGX-121 over asymptomatic spine MRI findings,
www.fiercebiotech.com
September 18, 2026 at 3:59 PM
Regenx said it was moving toward refiling, then the FDA hold hit and now there’s no near-term resubmission
That's not "timing problem". It raises real questions about whether the data package is strong enough #$RGNX
www.fiercebiotech.com/biotech/fda-...
That's not "timing problem". It raises real questions about whether the data package is strong enough #$RGNX
www.fiercebiotech.com/biotech/fda-...
#$RGNX Regenx keeps trying to frame this like a filing timing issue, but the bigger question is whether the therapy has actually shown enough...?
if the data were clearly strong, we probably would not be seeing repeated FDA pushback, a clinical hold, and no near-term resubmission. Strange.
if the data were clearly strong, we probably would not be seeing repeated FDA pushback, a clinical hold, and no near-term resubmission. Strange.
September 18, 2026 at 3:46 PM
#$RGNX Regenx keeps trying to frame this like a filing timing issue, but the bigger question is whether the therapy has actually shown enough...?
if the data were clearly strong, we probably would not be seeing repeated FDA pushback, a clinical hold, and no near-term resubmission. Strange.
if the data were clearly strong, we probably would not be seeing repeated FDA pushback, a clinical hold, and no near-term resubmission. Strange.
BioPharmCatalyst Weekly Watchlist: Top biotech stocks & key catalysts for Q3. Tickers: ABEO, XOMA, CCCC, BFRI, RGNX, MNOV, KYTX, IMMP, OCGN, CGEM. Full list: biopharmcatalyst.com/news www.biopharmcatalyst.com/news/2026/se...
September 11, 2026 at 8:15 PM
BioPharmCatalyst Weekly Watchlist: Top biotech stocks & key catalysts for Q3. Tickers: ABEO, XOMA, CCCC, BFRI, RGNX, MNOV, KYTX, IMMP, OCGN, CGEM. Full list: biopharmcatalyst.com/news www.biopharmcatalyst.com/news/2026/se...
🧵 1/5 🧬 REGENXBIO Inc. ($RGNX) — INSIDER BUY Alert
Director Gregory Austin Ciongoli bought 102,603 shares at $9.25 (~$0.95M).
Director Gregory Austin Ciongoli bought 102,603 shares at $9.25 (~$0.95M).
Insider Buying Week 01-02-26
This week's insider buying: Nike's CEO stepped in with $1M, plus director buys at Agree Realty, Enterprise Products, and Boston Omaha.
insomniachedge.com
September 5, 2026 at 11:00 PM
🧵 1/5 🧬 REGENXBIO Inc. ($RGNX) — INSIDER BUY Alert
Director Gregory Austin Ciongoli bought 102,603 shares at $9.25 (~$0.95M).
Director Gregory Austin Ciongoli bought 102,603 shares at $9.25 (~$0.95M).
First 30 bomb in a tournament !! and it was against + server players !!
RGNX-UHUS-J10C-FGL1
RGNX-UHUS-J10C-FGL1
September 2, 2026 at 1:28 AM
First 30 bomb in a tournament !! and it was against + server players !!
RGNX-UHUS-J10C-FGL1
RGNX-UHUS-J10C-FGL1
Newly appointed #$RGNX director Greg Ciongoli bought 102,603 shares for about $950,000 days after an FDA hold on Hunter syndrome therapy RGX-121. notreload.xyz/xy/new-regen...
New Regenxbio Director Buys Nearly $1M in Stock
Newly appointed Regenxbio director Greg Ciongoli bought 102,603 shares for about $950,000 days after an FDA hold on Hunter syndrome therapy RGX-121.
notreload.xyz
August 28, 2026 at 12:21 PM
Newly appointed #$RGNX director Greg Ciongoli bought 102,603 shares for about $950,000 days after an FDA hold on Hunter syndrome therapy RGX-121. notreload.xyz/xy/new-regen...
🚨 $RGNX
Ciongoli Gregory Austin () bought 102,603 shares at an average price of $9.2530 per common share. (Date: 2026-08-27)
Ciongoli Gregory Austin () bought 102,603 shares at an average price of $9.2530 per common share. (Date: 2026-08-27)
SEC Filing: RGNX
Click to view the official SEC document.
www.sec.gov
August 27, 2026 at 11:04 PM
🚨 $RGNX
Ciongoli Gregory Austin () bought 102,603 shares at an average price of $9.2530 per common share. (Date: 2026-08-27)
Ciongoli Gregory Austin () bought 102,603 shares at an average price of $9.2530 per common share. (Date: 2026-08-27)
🚨 $RGNX
Ciongoli Gregory Austin () filed Form 3 reporting no initial stock ownership.
Ciongoli Gregory Austin () filed Form 3 reporting no initial stock ownership.
SEC Filing: RGNX
Click to view the official SEC document.
www.sec.gov
August 27, 2026 at 11:03 PM
🚨 $RGNX
Ciongoli Gregory Austin () filed Form 3 reporting no initial stock ownership.
Ciongoli Gregory Austin () filed Form 3 reporting no initial stock ownership.
My girlfriend and I did "In the Blood" at karaoke earlier this week! I do recommend if you're not already familiar, one of the great chorus hooks of the decade imo www.youtube.com/watch?v=rGNX...
Better Than Ezra - In The Blood (Video)
YouTube video by betterthanezra
www.youtube.com
August 26, 2026 at 2:02 PM
My girlfriend and I did "In the Blood" at karaoke earlier this week! I do recommend if you're not already familiar, one of the great chorus hooks of the decade imo www.youtube.com/watch?v=rGNX...
🚨 $RGNX
On August 25, 2026, the Board of Directors of REGENXBIO Inc. , elected Gregory Ciongoli as a Class II director of the Company effective immediately.
On August 25, 2026, the Board of Directors of REGENXBIO Inc. , elected Gregory Ciongoli as a Class II director of the Company effective immediately.
SEC Filing: RGNX
Click to view the official SEC document.
www.sec.gov
August 25, 2026 at 9:11 PM
🚨 $RGNX
On August 25, 2026, the Board of Directors of REGENXBIO Inc. , elected Gregory Ciongoli as a Class II director of the Company effective immediately.
On August 25, 2026, the Board of Directors of REGENXBIO Inc. , elected Gregory Ciongoli as a Class II director of the Company effective immediately.
📊 Stock movers right now:
BTCT: $1.74 (+52.6%)
RGNX: $8.05 (-24.9%)
FWDI: $5.73 (+11.5%)
BMGL: $4.80 (-9.4%)
CLIR: $4.84 (+8.1%)
More: https://suggestionbox.live/planet-markets
BTCT: $1.74 (+52.6%)
RGNX: $8.05 (-24.9%)
FWDI: $5.73 (+11.5%)
BMGL: $4.80 (-9.4%)
CLIR: $4.84 (+8.1%)
More: https://suggestionbox.live/planet-markets
August 25, 2026 at 7:00 AM
📊 Stock movers right now:
BTCT: $1.74 (+52.6%)
RGNX: $8.05 (-24.9%)
FWDI: $5.73 (+11.5%)
BMGL: $4.80 (-9.4%)
CLIR: $4.84 (+8.1%)
More: https://suggestionbox.live/planet-markets
BTCT: $1.74 (+52.6%)
RGNX: $8.05 (-24.9%)
FWDI: $5.73 (+11.5%)
BMGL: $4.80 (-9.4%)
CLIR: $4.84 (+8.1%)
More: https://suggestionbox.live/planet-markets
Signal or noise? > RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO
Inc. Following Clinical Hold - WBOC TV >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharma #healthcare #pharmaceutical
Inc. Following Clinical Hold - WBOC TV >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharma #healthcare #pharmaceutical
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO
Inc. Following Clinical Hold - WBOC TV
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold WBOC TV
dlvr.it
August 25, 2026 at 12:30 AM
Signal or noise? > RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO
Inc. Following Clinical Hold - WBOC TV >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharma #healthcare #pharmaceutical
Inc. Following Clinical Hold - WBOC TV >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharma #healthcare #pharmaceutical
Small-cap stocks gapping down in trading, Mon Aug 24th - #$KAPA #$EDVA #$YIBO #$TRUG #$SMTK #$NBTX #$DFNS #$RGNX #$FLZH #$AIXC - More: crystalequityresearch.com/leading-indi... - #smallcap
Leading Indicators, Monday August 24, 2026 – Crystal Equity Research
crystalequityresearch.com
August 24, 2026 at 9:51 PM
🚨 JUST IN: $RGNX
FDA clinical hold on REGENXBIO's RGX-121 for MPS II; BLA resubmission not expected near term
#SEC #stocks #investing #RGNX #Regulatory
🔗 secwatch.observer
FDA clinical hold on REGENXBIO's RGX-121 for MPS II; BLA resubmission not expected near term
#SEC #stocks #investing #RGNX #Regulatory
🔗 secwatch.observer
August 24, 2026 at 9:35 PM
🚨 JUST IN: $RGNX
FDA clinical hold on REGENXBIO's RGX-121 for MPS II; BLA resubmission not expected near term
#SEC #stocks #investing #RGNX #Regulatory
🔗 secwatch.observer
FDA clinical hold on REGENXBIO's RGX-121 for MPS II; BLA resubmission not expected near term
#SEC #stocks #investing #RGNX #Regulatory
🔗 secwatch.observer
🚨 $RGNX
On August 24, 2026, REGENXBIO Inc. announced that it received communication from the U.S. Food and Drug Administration that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II , also known as Hunter Syndrome, was pla...
On August 24, 2026, REGENXBIO Inc. announced that it received communication from the U.S. Food and Drug Administration that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II , also known as Hunter Syndrome, was pla...
SEC Filing: RGNX
Click to view the official SEC document.
www.sec.gov
August 24, 2026 at 9:29 PM
🚨 $RGNX
On August 24, 2026, REGENXBIO Inc. announced that it received communication from the U.S. Food and Drug Administration that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II , also known as Hunter Syndrome, was pla...
On August 24, 2026, REGENXBIO Inc. announced that it received communication from the U.S. Food and Drug Administration that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II , also known as Hunter Syndrome, was pla...